← Eichor
Study identifier: NCT07362927 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

Condition: Diabetic Macular Edema (DME)  ·  Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

PhaseEARLY_Phase 1
Planned participants32
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this study is to evaluate the safety and efficacy of LX111 treatment of DME. This study will enroll participants aged ≥ 18 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.

This description comes directly from the study's public registry record.

Talk to the study team

Li Su  ·  +86 02136126254  ·  li.su@shgh.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Shanghai General HospitalShanghai, ChinaRecruiting
Zhongshan HospitalShanghai, ChinaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07362927